Myovant Sciences Ltd Stock News

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences press release (NYSE:MYOV): Q3 GAAP EPS of -$0.68 misses by $0.07.Revenue of $54.4M (+3842.0% Y/Y) in-line.

BASEL, Switzerland, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced financial results for the

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -15.25% and 0.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myovant Sciences (NYSE:MYOV) is scheduled to announce Q3 earnings results on Wednesday, January 26th, before market open.The consensus EPS Estimate is -$0.61 and the consensus

6 Top Biotech Ideas For 2022

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast an

BASEL, Switzerland, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and

Myovant Sciences (MYOV) sees total revenues to be in the range of $54 to $55M for the quarter ended Dec.31 compared to $1.4M in year ago quarter.Net product revenue is estimated to be…

BASEL, Switzerland, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced preliminary financial res

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief E

BASEL, Switzerland, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, Chief Exe

Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially. Nevertheless, there are powerful fundamental advancements that signal much more upsides going in

Equities analysts forecast that Myovant Sciences Ltd. (NYSE:MYOV) will post sales of $56.34 million for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Myovant Sciences earnings. The lowest sales estimate is $53.28 million and the highest is $58.40 million. Myovant Sciences posted sales of $1.38 million during the same []